Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Assembly Biosciences (ASMB) EBIT (2016 - 2025)

Historic EBIT for Assembly Biosciences (ASMB) over the last 9 years, with Q3 2025 value amounting to -$10.9 million.

  • Assembly Biosciences' EBIT rose 66.63% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year increase of 643.86%. This contributed to the annual value of -$45.4 million for FY2024, which is 2974.04% up from last year.
  • As of Q3 2025, Assembly Biosciences' EBIT stood at -$10.9 million, which was up 66.63% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' EBIT registered a high of -$9.9 million during Q1 2025, and its lowest value of -$62.9 million during Q4 2021.
  • For the 4-year period, Assembly Biosciences' EBIT averaged around -$18.3 million, with its median value being -$12.6 million (2023).
  • As far as peak fluctuations go, Assembly Biosciences' EBIT crashed by 45972.03% in 2021, and later soared by 4514.55% in 2024.
  • Assembly Biosciences' EBIT (Quarter) stood at -$62.9 million in 2021, then skyrocketed by 80.04% to -$12.6 million in 2023, then rose by 8.12% to -$11.5 million in 2024, then rose by 5.63% to -$10.9 million in 2025.
  • Its EBIT stands at -$10.9 million for Q3 2025, versus -$11.1 million for Q2 2025 and -$9.9 million for Q1 2025.